About Kallyope
Kallyope is a Healthcare company based in New York (United States) founded in 2014 by Charles Zuker, Richard Axel, and Tom Maniatis. The gut-brain axis is explored for therapeutic and nutritional innovations. Kallyope has raised $479 million across 6 funding rounds from investors including Illumina, ARE and StepStone Group. The company has 84 employees. Its chief executive, as recorded, is Jay Galeota. Kallyope offers products and services including Klarity Platform. Its focus areas include Life Sciences, Microbiome Therapeutics, Diversified and Genomics. Its legal entity is Kallyope Inc. Its competitors include Evelo Biosciences, Synlogic Therapeutics and Trace Genomics; 3 of its 3 listed competitors have raised funding.
Company details
Kallyope was founded in 2014 in New York, United States, as a biotechnology platform focused on the gut-brain axis. Technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics are integrated to study interactions between the brain and gut microbes. This approach is applied to identify microbiome-derived molecules that influence human behavior, leading to the development of therapeutics and nutritional products for health improvement.
- Headquarters New York, United States
- Employees 84
- Founders Charles Zuker, Richard Axel, Tom Maniatis
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website kallyope.com
- Social LinkedIn
- Legal Name Kallyope Inc
- Total Equity Funding$479M (USD)
in 6 rounds
- Latest Funding Round$8.2M (USD), Grant
May 2023
- InvestorsIllumina
& 20 more
- Employee Count84
Products & Services of Kallyope
Kallyope offers a comprehensive portfolio of products and services, including Klarity Platform.
Technology for discovering therapeutics in metabolic and neurological fields.
Funding Insights of Kallyope
Kallyope has successfully raised a total of $479M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $8.2 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $479M
- Total Rounds 6
- Last Round Grant — $8.2M
- First Round $44M
(Dec 2015)
- Investors Count 21
All 6 funding rounds of Kallyope with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | $8.2M | Grant | – | – | |
| Feb 2022 | $236M | Series D | – | Mubadala, TCG | |
| Mar 2020 | $112M | Series C | – | Illumina Ventures, Alexandria | |
| Dec 2018 | $21M | Series B | – | Bill Gates | |
| Feb 2018 | $66M | Series B | – | Lux Capital, Polaris Partners | |
| Dec 2015 | $44M | Series A | – | Lux Capital |
21 investors in total: 20 institutional and 1 angel.
Investors in Kallyope
Kallyope has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Illumina, ARE and StepStone Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Venture capital firm focused on multiple sectors | taocap.com | Marlborough, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
US private equity investments are managed by DNS Capital. | dnscap.com | Chicago, United States | ||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Diversified asset management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 2007 | stepstonegroup.com | New York, United States | |
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Multiple sectors are invested in by this single-family office. | New York, United States |
Investor details for Kallyope
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kallyope
57 people are tracked at Kallyope (20 in leadership, 13 in board & advisors, 24 in team); the tracked headcount is 84.
| Name | Role | Group |
|---|---|---|
Charles Zuker | Co-Founder | Leadership |
Richard Axel | Co-Founder | Leadership |
Tom Maniatis | Co-Founder | Leadership |
Jay Galeota | CEO | Leadership |
Jiajun Liu | VP & Head, Biometrics | Leadership |
Patrick Flanigan | CFO | Leadership |
Brett Lauring | CMO | Leadership |
Annemarie Vance | Senior Director & Head, Clinical Operations | Leadership |
Greg Rak | Vice President, Head Of Safety Assessment | Leadership |
Z. David Wang | Senior Director, Head Of Clinical Program And Portfolio | Leadership |
Robert Barretto | Senior Director, BD & Competitive Intelligence | Leadership |
David Ricardo Lopez | Head of Operations, Senior Director | Leadership |
Maury Spadoto | Senior Director & Head, Financial Planning & Analysis | Leadership |
Scott Brannigan | Head of Information Technology | Leadership |
Myung Shin | Vice President, Head Of Early Discovery Translation & In Vitro Pharmacology | Leadership |
Daniel Boisvert | Director, Clinical Operations | Leadership |
Hannah S. | Sr. Director, Corporate Controller | Leadership |
Michael Crutchlow | VP & Head, Translational Medicine | Leadership |
Justine Kupferman | Director, Neuroscience | Leadership |
Robert Saklatvala | Vice President | Leadership |
37 more people are available in the full profile.
Complete people profiles for Kallyope
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kallyope
3 dated milestones of Kallyope across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Kallyope is founded.
- Funding First funding round of $44.0M.
- Funding Latest funding round, Grant, of $8.2M.
Competitors of Kallyope
Kallyope has 3 listed competitors in our database, 3 of them funded. They include Evelo Biosciences, Synlogic Therapeutics and Trace Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| synlogictx.com | 2013 | Cambridge, United States | $34.4M | 85 | Engineered microbes are developed as programmable therapeutics for metabolic disorders. | |
| tracegenomics.com | 2015 | San Francisco, United States | $53.62M | 51 | Developer of technologies to diagnose soil health and soil-borne disease prediction |
Detailed competitors of Kallyope
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kallyope
The website of Kallyope (kallyope.com) receives about 2.9K visits a month and ranks #7,316,061 among all websites worldwide, #6,972 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▲ 25.8% vs previous month
- Global rank#7,316,061
among all websites
- Category rank#6,972
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.6
- Average visit18 sec
- DevicesDesktop 33% · Mobile 67%
Top companies in Microbiome Therapeutics
3 companies that operate in the same segment as Kallyope (Microbiome Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | 55 | ||
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | 12 | ||
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kallyope
Complete news archive for Kallyope
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kallyope
Kallyope was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Kallyope is headquartered in New York, United States. It is registered at New York, New York, United States.
Jay Galeota is the CEO of Kallyope, as recorded in our data.
Kallyope is a funded company, having raised a total of $479M across 6 funding rounds to date. The company's 1st funding round was a Series A of $44M, raised on Dec 2015.
Kallyope has 84 employees.
Kallyope was founded in 2014 in New York, United States, as a biotechnology platform focused on the gut-brain axis. Technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics are integrated to study interactions between the brain and gut microbes. This approach is applied to identify microbiome-derived molecules that influence human behavior, leading to the development of therapeutics and nutritional products for health improvement.
Kallyope's top competitors include Trace Genomics, Synlogic Therapeutics and Evelo Biosciences.
Kallyope offers Klarity Platform.
Kallyope has 21 investors. Key investors include Illumina, ARE, StepStone Group, Gates Foundation, and Mubadala.
Kallyope operates through Kallyope Inc.